<DOC>
	<DOCNO>NCT01579695</DOCNO>
	<brief_summary>The purpose observational , 10-year , prospective cohort study assess potential safety concern long-term exposure EGRIFTA® HIV-infected subject abdominal lipohypertrophy compare similar group subject expose EGRIFTA® .</brief_summary>
	<brief_title>Long-term Observational Study HIV Subjects Exposed EGRIFTA®</brief_title>
	<detailed_description />
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>All following inclusion criterion must fulfil : 1 . Subject give write informed consent ; 2 . Subject adult man woman ≥ 18 year old ; 3 . Subject HIV infection ; 4 . Subject physical evidence excess abdominal fat , determine examine study physician . 5 . Subject complete standard care assessment ( mammography , cervical PAP smear , colonoscopy blood work HIV1 RNA , CD4 cell count , renal , hepatic , hematology , PSA test , fast blood glucose , lipid panel ) prior enrol onto study . Exclusion criteria 1 4 base contraindication EGRIFTA® . 1 . Disruption hypothalamicpituitary axis , include condition hypophysectomy , hypopituitarism , pituitary tumor/surgery , head irradiation , head trauma ; 2 . Active malignancy ( newly diagnose recurrent ) 3 . Known hypersensitivity tesamorelin and/or mannitol 4 . Pregnancy lactation 5 . Use EGRIFTA® within 6 month prior baseline 6 . Failure complete standard care assessment list Section 5.2.1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV lipohypertrophy</keyword>
</DOC>